PE-22-28 Research Overview

Discovery and Structural Origins

PE-22-28 emerged from research into spadin — an endogenous peptide discovered in 2010 by Mazella and colleagues at the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC) in Nice, France. Spadin is a 17-amino acid peptide cleaved from the propeptide domain of sortilin (neurotensin receptor 3, NTSR3) — a multifunctional receptor involved in neurotrophin signalling, lipoprotein metabolism, and neurotransmitter receptor trafficking. The propeptide fragment released during sortilin maturation was found to act as a selective antagonist of the TREK-1 potassium channel — and this TREK-1 antagonism was subsequently identified as producing antidepressant-like behavioural effects in rodent models.

PE-22-28 is a truncated hexapeptide (spanning residues 22–28 of the spadin sequence, sequence: Ile-Glu-Glu-Leu-Lys-Ser) engineered to retain TREK-1 antagonist activity while improving on spadin's pharmacological limitations — particularly its short plasma half-life (approximately 30 minutes) and susceptibility to rapid proteolytic degradation. Structural optimisation studies identified PE-22-28 as demonstrating comparable or superior TREK-1 antagonist potency to full-length spadin, with modestly improved metabolic stability.

• Sequence: Ile-Glu-Glu-Leu-Lys-Ser (residues 22–28 of spadin)
• Molecular Weight: ~746 Da
• Primary Target: TREK-1 (KCNK2) two-pore domain potassium channel
• Parent Compound: Spadin (NTSR3/sortilin propeptide fragment)
• Onset of Action: Rapid — 4 days in rodent models (vs 2–3 weeks for SSRIs)
• Primary Research Models: Forced swim test, tail suspension, novelty suppressed feeding, corticosterone models

TREK-1: The Target Channel and Its Role in Depression

TREK-1 (TWIK-Related K⁺ Channel 1; gene: KCNK2) is a member of the two-pore domain (K2P) potassium channel family — background leak channels that set neuronal resting membrane potential and regulate neuronal excitability. Unlike voltage-gated or ligand-gated channels that open transiently, K2P channels are constitutively active, providing a continuous outward K⁺ current that hyperpolarises neurons and reduces their responsiveness to excitatory inputs.

TREK-1 is expressed throughout the brain with particularly high density in the cortex, hippocampus, and raphe nuclei — regions central to mood, emotion, and serotonin production. The critical connection to depression research emerged from TREK-1 knockout studies: TREK-1⁻/⁻ mice display a robust antidepressant-like phenotype across multiple behavioural paradigms (forced swim test, tail suspension, novelty-suppressed feeding), accompanied by enhanced serotonergic neurotransmission in the hippocampus and cortex. This finding established TREK-1 as a negative regulator of mood and serotonergic tone — and by implication, a pharmacological target for antidepressant drug development.

Mechanism of Action: TREK-1 Antagonism to Antidepressant Effect

PE-22-28 Antidepressant Signalling Cascade 1TREK-1 Antagonism: PE-22-28 binds and blocks TREK-1 channel conductance in raphe serotonergic neurons and hippocampal neurons, reducing outward K⁺ current and raising membrane potential toward threshold. 2Increased Neuronal Excitability: Reduced TREK-1 activity increases dorsal raphe serotonergic neuron firing rate and serotonin release into forebrain projection areas — hippocampus, prefrontal cortex, amygdala. 3Enhanced Serotonergic Tone: Elevated synaptic serotonin activates post-synaptic 5-HT receptors (particularly 5-HT1A and 5-HT4) in hippocampus and PFC — producing downstream cAMP and CREB pathway activation. 4BDNF Upregulation: CREB-mediated transcription drives BDNF expression in hippocampal neurons — the primary neurotrophic signal for adult hippocampal neurogenesis and synaptic plasticity. 5Hippocampal Neurogenesis: BDNF activates TrkB receptors on neural progenitor cells in the subgranular zone, stimulating proliferation and differentiation of new granule cells — the cellular substrate of sustained antidepressant effects.

Antidepressant Research Evidence

Rapid Onset: The Key Distinction

The most clinically significant feature of PE-22-28's antidepressant profile in research models is its onset speed. In the forced swim test (FST) and tail suspension test (TST) — the two most widely used acute antidepressant screening assays — PE-22-28 produces significant reductions in immobility (the behavioural correlate of depressive-like helplessness) after just 4 days of treatment in mice. Conventional SSRIs and tricyclic antidepressants require 14–21 days of treatment to produce equivalent effects in the same models — a delay that reflects the time required for receptor desensitisation, neuroplastic adaptations, and neurogenesis induction through the slower indirect serotonergic pathway.

PE-22-28's rapid effect is mechanistically explained: by directly blocking TREK-1, it immediately increases serotonergic tone within hours of administration, activating 5-HT receptor signalling and initiating BDNF/TrkB/neurogenesis cascades several steps earlier in the signalling chain than SSRIs, which must first block serotonin reuptake and then wait for adaptive receptor changes to produce net increased serotonergic signalling.

Corticosterone-Induced Depression Model

The most translational preclinical model for major depressive disorder (MDD) involves chronic corticosterone administration — which mimics the hypercortisolaemia of chronic stress and produces sustained depressive-like behavioural changes, hippocampal neurogenesis suppression, and reduced BDNF expression that parallel features of human MDD. In chronic corticosterone-treated mice, PE-22-28 administration over 14 days reversed behavioural despair metrics, restored hippocampal BDNF protein levels, and partially normalised subgranular zone progenitor cell proliferation — providing validation of its antidepressant mechanism in a more disease-relevant chronic stress model.

Neurogenesis Quantification

Adult hippocampal neurogenesis — the generation of new granule cells from progenitors in the subgranular zone of the dentate gyrus — is now established as a functional requirement for the behavioural effects of antidepressants in rodents: ablation of neurogenesis (by hippocampal irradiation) blocks the behavioural response to SSRIs and other antidepressants, implicating new neuron generation as a necessary downstream effector. BrdU/Ki67 immunohistochemistry in PE-22-28–treated mice demonstrates significantly increased subgranular zone progenitor proliferation compared to vehicle controls — directly confirming the neurogenic mechanism proposed from the TREK-1/5-HT/BDNF signalling chain.

Comparison to Spadin and Other Antidepressant Mechanisms

• Compound: PE-22-28 — Mechanism: TREK-1 antagonism → 5-HT ↑ → BDNF ↑ — Onset (Rodent): 4 days — Neurogenesis: Yes — confirmed — TREK-1 Selectivity: High
• Compound: Spadin (full 17aa) — Mechanism: TREK-1 antagonism — Onset (Rodent): 4 days — Neurogenesis: Yes — TREK-1 Selectivity: High (shorter t½)
• Compound: Fluoxetine (SSRI) — Mechanism: SERT inhibition → 5-HT ↑ (indirect) — Onset (Rodent): 14–21 days — Neurogenesis: Yes (requires chronic) — TREK-1 Selectivity: N/A
• Compound: Ketamine — Mechanism: NMDA-R blockade → AMPA-R activation → BDNF — Onset (Rodent): Hours–1 day — Neurogenesis: Yes (rapid) — TREK-1 Selectivity: N/A
• Compound: Semax — Mechanism: BDNF upregulation; dopaminergic — Onset (Rodent): Days — Neurogenesis: Indirect (BDNF) — TREK-1 Selectivity: N/A

Research Significance > > PE-22-28 represents a mechanistically novel antidepressant research tool targeting a potassium channel — a class entirely distinct from monoamine reuptake inhibitors, NMDA receptor antagonists, and other established antidepressant mechanisms. Its rapid-onset antidepressant profile positions it alongside ketamine as a candidate for research into fast-acting antidepressant mechanisms, but through a non-glutamatergic pathway with potentially different side-effect implications. The TREK-1 channel system is an emerging target in psychiatric research with broad implications for anxiety, epilepsy, pain, and neuroprotection beyond depression.

Anxiety Research

Beyond depression, PE-22-28 and parent compound spadin have been assessed in anxiety paradigms. In the open field test — where reduced exploration of the centre zone indicates anxious behaviour — spadin-treated mice demonstrated significantly greater central zone exploration, suggesting an anxiolytic effect. In the elevated plus maze (EPM), a reduction in closed arm preference (indicative of reduced anxiety) was also observed. These findings are consistent with TREK-1's expression in the amygdala — a region central to fear conditioning and anxiety — and its role in regulating amygdalar neuronal excitability. Whether these anxiolytic effects are mechanistically linked to the serotonergic enhancement or represent independent TREK-1 actions in anxiety circuits is an open research question.

Stability and Research Considerations

As a hexapeptide of approximately 746 Da, PE-22-28 is among the smallest compounds in the research peptide class — conferring excellent aqueous solubility and reconstitution ease. Lyophilised PE-22-28 is stable at −20°C for 24+ months. Reconstitution in bacteriostatic water is standard. Its primary pharmacological limitation is plasma half-life — estimated at below 60 minutes in rodent plasma based on extrapolation from spadin stability data — requiring multiple daily administrations for sustained receptor occupation in chronic research protocols. Intranasal delivery is being explored as a route offering more direct CNS delivery, but formal pharmacokinetic data for PE-22-28 via intranasal route has not been published.

Research Use Only. Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. PE-22-28 is not approved by the FDA or any regulatory agency for human therapeutic use. The evidence base is entirely preclinical, originating from a small number of French research institutions. This content does not constitute medical advice, diagnosis, or treatment recommendation. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Mazella J, et al. "Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design." *PLoS Biol*. 2010;8(4):e1000355.

1. Moha Ou Maati H, et al. "Spadin as a new antidepressant: absence of TREK-1-related side effects." *Neuropharmacology*. 2012;62(1):278–288.

1. Djillani A, et al. "Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity." *Front Pharmacol*. 2017;8:643.

1. Lauritzen I, et al. "Cross-talk between the mechano-gated K2P channel TREK-1 and the actin cytoskeleton mediates cell shape changes." *EMBO J*. 2005;24(23):4093–4105.

1. Bhaskaran MD, Smith BN. "Effects of TREK-1 on synaptic plasticity and depression-like behavior." *Br J Pharmacol*. 2010;162(3):781–793.

1. Djillani A, et al. "PE-22-28, a novel antidepressant spadin analogue with improved metabolic stability and efficacy in chronic stress models." *Neuropharmacology*. 2019;155:195–204.